Differential Plasma Metabolites between High- and Low-Grade Meningioma Cases

Abstract

Meningiomas (MGMs) are currently classified into grades I, II, and III. High-grade tumors are correlated with decreased survival rates and increased recurrence rates. The current grading classification is based on histological criteria and determined only after surgical tumor sampling. This study aimed to identify plasma metabolic alterations in meningiomas of different grades, which would aid surgeons in predefining the ideal surgical strategy. Plasma samples were collected from 51 patients with meningioma and classified into low-grade (LG) (grade I; n = 43), and high-grade (HG) samples (grade II, n = 5; grade III, n = 3). An untargeted metabolomic approach was used to analyze plasma metabolites. Statistical analyses were performed to select differential biomarkers among HG and LG groups. Metabolites were identified using tandem mass spectrometry along with database verification. Five and four differential biomarkers were identified for HG and LG meningiomas, respectively. To evaluate the potential of HG MGM metabolites to differentiate between HG and LG tumors, a receiving operating characteristic curve was constructed, which revealed an area under the curve of 95.7%. This indicates that the five HG MGM metabolites represent metabolic alterations that can differentiate between LG and HG meningiomas. These metabolites may indicate tumor grade even before the appearance of histological features.

Metabolomics Approach Reveals Important Glioblastoma Plasma Biomarkers for Tumor Biology

“…This compound is composed of a sphingosine C18 carbon chain associated with the fatty acid C24, which is present at increased levels in human glioma cell lines [53,54]. Additionally, the level of 3-O-sulfogalactosylceramide has been found to be increased in the plasma of patients with meningioma [55] and different tumors [56][57][58] and has been associated with metastasis risk [59]. In addition, sulfated glycolipids are known to attach to adhesion molecules, especially P-selectin, one of the main membrane glycoproteins responsible for cell adhesion in endothelial cells, [60] and are overexpressed in GB cells [61].…”

Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring

“…In addition to bladder cancer, an OPLS-DA score plot by Kurokawa et al. showed patients with meningioma were clustered according to different grades ( 147 ). Finally, Arginyl-Proline, PS (44:6), 3-O-sulfogalactosylceramide (42:2), PS (36:5) and CER (40:1) were identified as serum metabolic markers for high-grade meningiomas.…”

“…One reported NMR spectroscopic metabolic panel could distinguish patients with low-grade bladder cancer (n = 54) from those with high-grade bladder cancer (n = 41) through a permutation analysis-validated OPLS-DA model comprising five metabolites (leucine, histidine, alanine, 3-methyl-2-oxovalerate, and tyrosine) (146). In addition to bladder cancer, an OPLS-DA score plot by Kurokawa et al showed patients with meningioma were clustered according to different grades (147). Finally, Arginyl-Proline, PS (44:6), 3-O-sulfogalactosylceramide (42:2), PS (36:5) and CER (40:1) were identified as serum metabolic markers for high-grade meningiomas.…”

Comparative Analysis of Amino Acid Profiles in Patients with Glioblastoma and Meningioma Using Liquid Chromatography Electrospray Ionization Tandem Mass Spectrometry (LC-ESI-MS/MS)

“…The use of LC-MS/MS methods for small molecules in biological fluids is becoming increasingly preferred because they have higher sensitivity and better reliability in complex biological fluids. Recent studies have shown that the use of metabolomic analysis with mass spectrometry detection allowed the identification of biomarkers differentiating patients with CNS tumors from healthy people or enabling the differentiation of low-and high-grade tumors [34,[36][37][38][39][40][41].…”